Esperion Wins FDA Approval for First Heart Medicine, Nexletol

February 25, 2020

Esperion won FDA approval for Nexletol (bempedoic acid) to treat for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C., according to the agency’s website.